-+ 0.00%
-+ 0.00%
-+ 0.00%

The FDA Has Accepts Aquestive Therapeutics' New Drug Application For Anaphylm For Type 1 Allergic Reactions, Including Anaphylaxis, With PDUFA Target Action Date Of January 31, 2026

Benzinga·06/16/2025 11:04:57
Listen to the news

If approved by the FDA, Anaphylm would be the first and only orally delivered epinephrine option for the treatment of severe allergic reactions in the United States.